SOURCE: Licensing Executives Society

October 01, 2007 11:39 ET

U.S. Patent Law Changes to Be Analyzed at Licensing Executives Society Meeting

Event to be Held in Vancouver October 14-18, 2007

VANCOUBER, BC--(Marketwire - October 1, 2007) - Legal and regulatory changes in U.S. patent laws have broad implications for businesses across North America. Consider this:

--  The U.S. Congress is about to pass sweeping patent reform that will
    fundamentally change how patents are issued and how they can be challenges
--  The U.S. Supreme Court has overturned lower court rulings on the
    "obviousness" test for patents, setting a precedent that will alter how
    patents can be deemed valid
--  The rise of hedge funds is affecting how many licensing deals are now
--  New U.S. Patent and Trademark Office is tightening rules on patent
    claims and continuations effective November 1, 2007
--  The U.S. Department of Justice and Federal Trade Commission is
    changing antitrust enforcement practices regarding intellectual property
    that may help future licensing deals

What does all this mean for Canadian and U.S. businesses? Get answers at the Licensing Executives Society Annual Meeting, October 14-18, 2007, at the Vancouver Convention and Exhibit Centre, Vancouver, British Columbia, Canada.

More than 1,000 corporate business development officers, patent attorneys, intellectual property licensing consultants, and other members of the Licensing Executives Society will discuss these current issues.

Other meeting highlights include:

--  Licensing in the Global Marketplace for High Technology - Marshall
    Phelps, Corporate Vice President and Deputy General Counsel for Microsoft
    Corporation, who oversees an IP portfolio that includes 3,000 patents and
    11,000 trademarks, will analyze IP licensing trends in the technology
--  Licensing or M&A? - Acquisitions of biotech companies reached $30
    billion in 2006, up from $25 billion in 2005. How does this affect IP
    licensing in the biopharma sector? A panel of experts from Merck, Amgen,
    Genentech, Biogen, Gilead, and Recombinant Capital will explore the issue.
--  Watts Wacker Speaks - One of the world's most respected futurists,
    Watts Wacker is founder and director of FirstMatter LLC. He is considered
    one of the most influential minds in modern business and recently co-
    authored a book titled "Deviant's Advantage."
--  Deals of Distinction - Each year, LES awards "Deals of Distinction"
    recognition to the top IP licensing deals in several industry sectors. Find
    out the 2007 winners and what made their deals unique.

Press Registration: For press registration, contact Al Rickard at 703-402-9713 or Need more information? Visit the Licensing Executives Society Web site.

Contact Information